Read on Twitter
Important caveat on # of events, but hard to look at this data and not be very excited. https://twitter.com/MaxNisen/status/1313876165938024448
Baseline characteristics.
**I anticipate the definition of who is 'high risk' is going to be a major issue for payers to decide who gets this therapy (depending on how EUA, if it goes through, is written)
The slide show with the Lilly data is here:
https://investor.lilly.com/static-files/a6dfdc90-3e16-4511-9a5d-f744b7568276
**I anticipate the definition of who is 'high risk' is going to be a major issue for payers to decide who gets this therapy (depending on how EUA, if it goes through, is written)
The slide show with the Lilly data is here:
https://investor.lilly.com/static-files/a6dfdc90-3e16-4511-9a5d-f744b7568276
the safety data look good, combined with what is known about safety of regeneron antibody so far.
Lilly has not opened up compassionate use it says in its conference call - they specify this is because of urgency of recruiting for clinical trials. 
They are stressing that drug should be available for EUA rather than rely on compassionate use.
They are stressing that drug should be available for EUA rather than rely on compassionate use.
Important caveat - they've applied for EUA for the mono therapy in high risk patients based on AGE and Weight, not the combo therapy, which will be later in fall.
They have 1 million doses of mono available they say.
They have 1 million doses of mono available they say.
